Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

KETAN D DOSHI

Allopathic & Osteopathic Physicians Internal Medicine Medical Oncology

NPI
1750573069
CMS profile
351845
Location
OCALA, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$22,329.56

243 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

Nature of paymentAmountRecords
Consulting Fee $14,957.50 4
Food and Beverage $4,297.95 224
Travel and Lodging $3,074.11 15

By paying entity

PY2019 · entire year · sorted by reported total

Page 5 of 5; records 201–243 of 243 matching records. This page contains 43 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

KETAN D DOSHI

NPI 1750573069 · CMS profile ID 351845

Allopathic & Osteopathic Physicians / Internal Medicine / Medical Oncology

OCALA, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 5 of 5; records 201–243 of 243 matching records. This page contains 43 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1750573069?year=2019&recipient=provider&page=5#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
KETAN D DOSHI, NPI 1750573069, CMS profile ID 351845. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 5 of 5; records 201–243 of 243 matching records. This page contains 43 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1750573069?year=2019&recipient=provider&page=5#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). KETAN D DOSHI, NPI 1750573069, CMS profile ID 351845. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 5 of 5; records 201–243 of 243 matching records. This page contains 43 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1750573069?year=2019&recipient=provider&page=5#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
KETAN D DOSHI, NPI 1750573069, CMS profile ID 351845, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 5 of 5; records 201–243 of 243 matching records. This page contains 43 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1750573069?year=2019&recipient=provider&page=5#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

243 matching records · $22,329.56 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 243 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 201–243 of 243.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
E.R. Squibb & Sons, L.L.C. $14.5103/04/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 651428223 CMS
Novartis Pharmaceuticals Corporation $20.2003/01/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659015311 CMS
AstraZeneca Pharmaceuticals LP $10.9402/28/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 688770361 CMS
Genentech USA, Inc. $17.2402/27/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681242895 CMS
Seattle Genetics, Inc. $11.2802/26/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 678793787 CMS
Lilly USA, LLC $12.2102/22/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657941581 CMS
Lilly USA, LLC $1.2902/22/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657945071 CMS
Lilly USA, LLC $0.2902/22/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657948453 CMS
Merck Sharp & Dohme Corporation $90.7802/20/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695275542 CMS
Merck Sharp & Dohme Corporation $19.6302/20/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695300875 CMS
EISAI INC. $18.0102/19/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697000869 CMS
Janssen Biotech, Inc. $15.4302/19/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658405681 CMS
Genentech USA, Inc. $15.0802/15/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681200231 CMS
Astellas Pharma US Inc $17.8402/14/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 655542951 CMS
E.R. Squibb & Sons, L.L.C. $10.8602/13/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 651428215 CMS
E.R. Squibb & Sons, L.L.C. $1.4102/13/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 651428221 CMS
SANOFI-AVENTIS U.S. LLC $11.1502/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 693919719 CMS
EISAI INC. $20.7702/11/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697041497 CMS
Merck Sharp & Dohme Corporation $12.3002/08/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695253749 CMS
Regeneron Healthcare Solutions, Inc. $10.0702/06/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673371319 CMS
Janssen Biotech, Inc. $13.3901/31/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658405677 CMS
E.R. Squibb & Sons, L.L.C. $11.5501/29/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 651428217 CMS
Lilly USA, LLC $1.1201/29/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657927687 CMS
Lilly USA, LLC $14.6101/28/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657945073 CMS
Lilly USA, LLC $0.2201/28/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657948455 CMS
AstraZeneca Pharmaceuticals LP $41.2901/25/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 688757849 CMS
GENZYME CORPORATION $17.5601/23/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 693913621 CMS
Janssen Biotech, Inc. $8.4401/22/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658405673 CMS
Celgene Corporation $22.0101/21/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672725993 CMS
Janssen Biotech, Inc. $2.4101/21/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658405669 CMS
Ipsen Biopharmaceuticals, Inc $11.3001/17/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 640643097 CMS
E.R. Squibb & Sons, L.L.C. $102.7001/16/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 651428283 CMS
Takeda Pharmaceuticals U.S.A., Inc. $10.8901/16/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697383501 CMS
Genentech USA, Inc. $9.9001/15/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681381249 CMS
Seattle Genetics, Inc. $18.5801/14/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 678793767 CMS
Lilly USA, LLC $0.7101/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657931179 CMS
Lilly USA, LLC $0.2401/11/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657948451 CMS
Array BioPharma Inc. $18.1701/10/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 700971851 CMS
Janssen Biotech, Inc. $3.8501/10/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658405665 CMS
Lilly USA, LLC $14.7301/10/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657934645 CMS
Janssen Biotech, Inc. $2.8401/09/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658405659 CMS
E.R. Squibb & Sons, L.L.C. $20.5801/08/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 651428211 CMS
PFIZER INC. $12.6501/04/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672377549 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $22,329.56 243
PY2020 $15,953.99 116
PY2021 $13,460.05 156
PY2022 $23,637.18 228
PY2023 $11,303.60 179
PY2024 $17,642.92 199
PY2025 $14,897.53 193

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $401,567.60 27
PY2024 Principal investigator $440,923.65 31
PY2023 Principal investigator $223,882.93 22
PY2022 Principal investigator $29,742.36 6
PY2021 Principal investigator $67,286.76 6
PY2020 Principal investigator $60,363.41 12
PY2019 Recipient $8,450.00 1
PY2019 Principal investigator $19,280.80 6

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

27 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $5,487.80 12/02/2025 Non-covered Recipient Entity
OCALA ONCOLOGY CENTER PL
Study of Ibrutinib and Rituximab in Treatment NaAve Follicular Lymphoma No dispute reported 06/30/2026 1202526320
Principal investigator 1 ABBVIE INC. $1,596.42 12/02/2025 Non-covered Recipient Entity
OCALA ONCOLOGY CENTER PL
Study of Ibrutinib and Rituximab in Treatment NaAve Follicular Lymphoma No dispute reported 06/30/2026 1202526322
Principal investigator 1 Epizyme, Inc. $2,762.91 12/01/2025 Non-covered Recipient Entity
Ocala Oncology Center
Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma No dispute reported 06/30/2026 1184282339
Principal investigator 1 Epizyme, Inc. $2,280.55 12/01/2025 Non-covered Recipient Entity
Ocala Oncology Center
Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma No dispute reported 06/30/2026 1184282341
Principal investigator 1 Epizyme, Inc. $2,280.55 12/01/2025 Non-covered Recipient Entity
Ocala Oncology Center
Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma No dispute reported 06/30/2026 1184282343
Principal investigator 1 Epizyme, Inc. $2,762.91 12/01/2025 Non-covered Recipient Entity
Ocala Oncology Center
Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma No dispute reported 06/30/2026 1184282345
Principal investigator 1 Epizyme, Inc. $2,280.55 12/01/2025 Non-covered Recipient Entity
Ocala Oncology Center
Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma No dispute reported 06/30/2026 1184282347
Principal investigator 1 Epizyme, Inc. $2,280.55 10/16/2025 Non-covered Recipient Entity
Ocala Oncology Center
Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma No dispute reported 06/30/2026 1184282333
Principal investigator 1 Epizyme, Inc. $2,762.91 10/16/2025 Non-covered Recipient Entity
Ocala Oncology Center
Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma No dispute reported 06/30/2026 1184282335
Principal investigator 1 Epizyme, Inc. $2,280.55 10/16/2025 Non-covered Recipient Entity
Ocala Oncology Center
Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma No dispute reported 06/30/2026 1184282337
Principal investigator 1 Mirati Therapeutics, Inc. $2,500.00 10/09/2025 Non-covered Recipient Entity
Ocala Oncology Center, Pl
Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1 No dispute reported 06/30/2026 1236530869
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $88.99 09/30/2025 Non-covered Recipient Entity
Ocala Oncology Center
A Randomized, Double-Blind, Phase 3 Trial of Adagrasib plus Pembrolizumab plus Chemotherapy vs. Placebo plus Pembrolizumab plus Chemotherapy in Participants with Previously Untreated, Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer with KRAS G12C Mutation (KRYSTAL-4) No dispute reported 06/30/2026 1235995024
Principal investigator 1 Celgene Corporation $10,240.00 08/27/2025 Non-covered Recipient Entity
Ocala Oncology Center
A Phase 3, Two-Stage, Randomized, Multicenter, Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Subjects with Relapsed or Refractory Multiple Myeloma (RRMM) No dispute reported 06/30/2026 1222306215
Principal investigator 1 ABBVIE INC. $19,991.00 05/01/2025 Non-covered Recipient Entity
OCALA ONCOLOGY CENTER PL
Study of Ibrutinib and Rituximab in Treatment NaAve Follicular Lymphoma No dispute reported 06/30/2026 1202480885
Principal investigator 1 ABBVIE INC. $9,923.00 05/01/2025 Non-covered Recipient Entity
OCALA ONCOLOGY CENTER PL
Study of Ibrutinib and Rituximab in Treatment NaAve Follicular Lymphoma No dispute reported 06/30/2026 1202480887
Principal investigator 1 ABBVIE INC. $32,697.00 05/01/2025 Non-covered Recipient Entity
OCALA ONCOLOGY CENTER PL
Study of Ibrutinib and Rituximab in Treatment NaAve Follicular Lymphoma No dispute reported 06/30/2026 1202480889
Principal investigator 1 Epizyme, Inc. $419.17 04/30/2025 Non-covered Recipient Entity
Ocala Oncology Center
Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma No dispute reported 06/30/2026 1184282329
Principal investigator 1 Epizyme, Inc. $2,945.16 04/30/2025 Non-covered Recipient Entity
Ocala Oncology Center
Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma No dispute reported 06/30/2026 1184282331
Principal investigator 1 Mirati Therapeutics, Inc. $889.38 04/24/2025 Non-covered Recipient Entity
Ocala Oncology Center, Pl
A Randomized Phase 3 Study of MRTX849 in Combination With Cetuximab Versus Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation With Disease Progression On or After Standard First-Line Therapy No dispute reported 06/30/2026 1236530864
Principal investigator 1 Eli Lilly and Company $1,268.96 04/23/2025 Non-covered Recipient Entity
OCALA ONCOLOGY CENTER, P.L.
SUNRAY-01 A GLOBAL PIVOTAL STUDY IN PARTICIPANTS WITH KRAS G12C-MUTANT LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER COMPARING FIRST LINE TREATMENT OF LY3537982 AND PEMBROLIZUMAB VS PLACEBO AND PEMBROLIZUMAB IN THOSE WITH PD L1 EXPRESSION 50% OR LY3537982 AND PEMBROLIZUMAB PEMETREXED PLATINUM VS PLACEBO AND PEMBROLIZUMAB PEMETREXED PLATINUM REGARDLESS OF PD-L1 EXPRESSION No dispute reported 06/30/2026 1187888850
Principal investigator 1 Epizyme, Inc. $2,591.59 03/20/2025 Non-covered Recipient Entity
Ocala Oncology Center
Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma No dispute reported 06/30/2026 1184282327
Principal investigator 1 Mirati Therapeutics, Inc. $13,039.34 03/19/2025 Non-covered Recipient Entity
Ocala Oncology Center, Pl
Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation (KRYSTAL-10) No dispute reported 06/30/2026 1236530859
Principal investigator 1 Epizyme, Inc. $156.00 03/07/2025 Non-covered Recipient Entity
Ocala Oncology Center
Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma No dispute reported 06/30/2026 1184282325
Principal investigator 1 Epizyme, Inc. $4,082.40 02/19/2025 Non-covered Recipient Entity
Ocala Oncology Center
Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma No dispute reported 06/30/2026 1184282321
Principal investigator 1 Epizyme, Inc. $2,762.91 02/19/2025 Non-covered Recipient Entity
Ocala Oncology Center
Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma No dispute reported 06/30/2026 1184282323
Principal investigator 1 Eli Lilly and Company $248,197.00 01/28/2025 Non-covered Recipient Entity
OCALA ONCOLOGY CENTER, P.L.
SUNRAY-01 A GLOBAL PIVOTAL STUDY IN PARTICIPANTS WITH KRAS G12C-MUTANT LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER COMPARING FIRST LINE TREATMENT OF LY3537982 AND PEMBROLIZUMAB VS PLACEBO AND PEMBROLIZUMAB IN THOSE WITH PD L1 EXPRESSION 50% OR LY3537982 AND PEMBROLIZUMAB PEMETREXED PLATINUM VS PLACEBO AND PEMBROLIZUMAB PEMETREXED PLATINUM REGARDLESS OF PD-L1 EXPRESSION No dispute reported 06/30/2026 1187888848
Principal investigator 1 Celgene Corporation $23,000.00 01/24/2025 Non-covered Recipient Entity
Ocala Oncology Center
A Phase 3, Two-Stage, Randomized, Multicenter, Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Subjects with Relapsed or Refractory Multiple Myeloma (RRMM) No dispute reported 06/30/2026 1222306293